| |
| Cost-effectiveness analysis of individualized mycophenolate mofetil dosing in kidney transplant patients in the APOMYGRE trial |
| Rousseau A, Laroche ML, Venisse N, Loichot-Roselmac C, Turcant A, Hoizey G, Compagnon P, Hary L, Debruyne D, Saivin S, Jacqz-Aigrain E, Buchler M, Villeneuve C, Vergnenegre A, Le Meur Y, Marquet P |
|
|
| |
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Rousseau A, Laroche ML, Venisse N, Loichot-Roselmac C, Turcant A, Hoizey G, Compagnon P, Hary L, Debruyne D, Saivin S, Jacqz-Aigrain E, Buchler M, Villeneuve C, Vergnenegre A, Le Meur Y, Marquet P. Cost-effectiveness analysis of individualized mycophenolate mofetil dosing in kidney transplant patients in the APOMYGRE trial. Transplantation 2010; 89(10): 1255-1262 Indexing Status Subject indexing assigned by NLM MeSH Adrenal Cortex Hormones /therapeutic use; Adult; Aged; Ambulatory Care /economics; Antibodies, Monoclonal /therapeutic use; Female; Graft Rejection /epidemiology /immunology /prevention & Histocompatibility Testing; Humans; Immunosuppression /economics /methods; Immunosuppressive Agents /economics /therapeutic use; Kidney Transplantation /immunology /mortality; Male; Middle Aged; Mycophenolic Acid /analogs & Recombinant Fusion Proteins /therapeutic use; Reoperation /economics /statistics & Switzerland; Treatment Failure; control; derivatives /economics /therapeutic use; numerical data AccessionNumber 22010001173 Date bibliographic record published 02/02/2011 |
| |
|
|
